 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer's Disease on Schedule to Complete Treatment in June 2024...

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

Vaccinex GAAP EPS of -$1.09, revenue of $0.02M...

Vaccinex GAAP EPS of -$1.09, revenue of $0.02M

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex reports Q3 EPS ($1.09) vs. ($1.67) last year

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with...

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex, Inc. (NASDAQ:VCNX  Get Free Report) was the recipient of a large decrease in short interest in October. As of October 15th, there was short interest totalling 198,000 shares, a...

Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Down 37.8% in October

Vaccinex announces presentation of findings for pepinemab

Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient bloodROCHESTER, N.Y., Oct...

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ( Vaccinex or the Company ), a clinical-stage biotechnology company pioneering a differentiated approach to...

Vaccinex Announces Pricing of $9.6 Million Public Offering

Vaccinex to present update on PDAC/Pepinemab study, new ActivMAb application

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Watchers	5,604
52-Wk Low	$0.5801
52-Wk High	$12.36

Market Cap	$7.75M
Volume (M)	157,533.00
52-Wk High	$12.36
52-Wk Low	$0.5801

VCNX Vaccinex Inc

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community